HGH

Human growth hormone (HGH), designated pharmacologically as somatropin in its recombinant form, is a 191-amino-acid, single-chain, non-glycosylated polypeptide of approximately 22,124 daltons produced by recombinant DNA technology in Escherichia coli or mammalian cell expression systems. The compound is structurally and functionally identical to the predominant 22-kDa isoform of endogenous somatotropin secreted by somatotropic cells of the anterior pituitary gland. Recombinant somatropin binds to the extracellular domain of the transmembrane growth hormone receptor (GHR), inducing receptor dimerization and activation of the Janus kinase 2 (JAK2) signaling cascade, with downstream phosphorylation of signal transducers and activators of transcription (STAT1, STAT3, STAT5), mitogen-activated protein kinase (MAPK/ERK), and phosphatidylinositol 3-kinase (PI3K/Akt) pathways. The principal systemic mediator of somatropin action is insulin-like growth factor 1 (IGF-1), a 70-amino-acid peptide synthesized predominantly in hepatocytes under direct GH receptor stimulation and released into the circulation bound to IGF-binding proteins (IGFBPs), principally IGFBP-3 in a ternary complex with the acid-labile subunit (ALS). The GH/IGF-1 axis governs linear bone growth in children, anabolic protein metabolism, lipolysis, glucose counter-regulation, and tissue repair across the lifespan.

The clinical development of exogenous growth hormone spans seven decades. Maurice Raben administered cadaveric pituitary-derived human growth hormone to a growth-hormone-deficient child in 1958, establishing proof of concept for replacement therapy. Cadaveric extraction remained the sole source until 1985, when reports of iatrogenic Creutzfeldt-Jakob disease (CJD) in recipients of pituitary-derived hormone prompted immediate suspension of cadaveric programs worldwide. Genentech received United States Food and Drug Administration (FDA) approval in October 1985 for somatrem (methionyl-HGH, Protropin), the first recombinant growth hormone product, followed by approval of somatropin (Humatrope, Eli Lilly) in 1987. As of 2026, multiple recombinant somatropin formulations are FDA-approved for pediatric growth hormone deficiency (GHD), Turner syndrome, Prader-Willi syndrome, small for gestational age (SGA) with failure of catch-up growth, idiopathic short stature (ISS), SHOX deficiency, chronic renal insufficiency, and Noonan syndrome in children, and for adult GHD and HIV-associated wasting. Long-acting formulations (somapacitan, somatrogon, lonapegsomatropin) have been approved since 2020 to reduce injection burden from daily to weekly administration.

Pharmacokinetics of subcutaneous somatropin are characterized by slow absorption from the injection depot (time to peak plasma concentration 3 to 5 hours), absolute bioavailability of approximately 70 to 80 percent, volume of distribution of approximately 0.07 L/kg (intravenous) to 1.3 L/kg (subcutaneous, apparent), and elimination half-life of approximately 3 to 4 hours following subcutaneous administration compared to 0.36 hours following intravenous injection. Clearance occurs principally through hepatic and renal proteolytic catabolism. The pharmacodynamic effect, mediated through sustained elevation of circulating IGF-1, persists substantially longer than the plasma half-life of the parent molecule, with IGF-1 levels remaining elevated for 18 to 28 hours after a single subcutaneous dose.

Clinical evidence for somatropin in pediatric GHD is extensive and unequivocal: meta-analyses of controlled trials demonstrate mean adult height gains of 4 to 8 centimeters above predicted untreated height over treatment courses of 3 to 10 years. In adults with documented GHD, randomized placebo-controlled trials demonstrate reduction of trunk fat mass (8 to 16 percent), increase in lean body mass (2 to 5 kg), improvement in bone mineral density at lumbar spine and femoral neck, improvement in lipid profiles (reduction in LDL cholesterol, increase in HDL cholesterol), and improvement in quality-of-life measures. The principal adverse events of somatropin therapy are dose-dependent and related to fluid retention: peripheral edema, arthralgia, myalgia, carpal tunnel syndrome, and paresthesia, occurring more frequently in adults than in children and generally resolving with dose reduction. Insulin resistance with impaired glucose tolerance is a recognized metabolic consequence of supraphysiologic GH exposure and requires monitoring. Long-term surveillance data from registries including KIGS, HypoCCS, NordiNet IOS, and the French SAGhE cohort have not demonstrated a consistent increase in de novo malignancy risk in patients treated for GHD without pre-existing risk factors, although the SAGhE study reported a modestly elevated standardized mortality ratio in patients treated with higher doses during childhood.

This monograph reviews the molecular biology, structural chemistry, and signal transduction pharmacology of recombinant somatropin; the comprehensive pharmacokinetic record; the clinical evidence base across pediatric and adult GHD, body composition, bone metabolism, and investigational applications; sourcing, reconstitution, and handling considerations for research use; stack interactions with secretagogues, IGF-1, insulin, and thyroid hormones; the adverse event and long-term safety profile; and a structured comparative assessment of five alternative approaches to GH axis modulation (sermorelin, tesamorelin, CJC-1295, ipamorelin, and ibutamoren/MK-677) against recombinant somatropin on five competency standards.